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Abstract
Background
Perioperative antibiotic prophylaxis in non-infected orthopedic surgery is evident, in contrast
to prophylaxis during surgery for infection. Epidemiological data are lacking for this particular
situation.
Methods and findings
It is a single-center cohort on iterative surgical site infections (SSIs) in infected orthopedic
patients. We included 2480 first episodes of orthopedic infections (median age 56 years and
833 immune-suppressed): implant-related infections (n = 648), osteoarticular infections
(1153), and 1327 soft tissue infections. The median number of debridement was 1 (range,
1–15 interventions). Overall, 1617 infections (65%) were debrided once compared to 862
cases that were operated multiple times (35%). Upon iterative intraoperative tissue sam-
pling, we detected pathogens in 507 cases (507/862; 59%), of which 241 (242/507; 48%)
corresponded to the initial species at the first debridement. We witnessed 265 new SSIs
(11% of the cohort) that were resistant to current antibiotic therapy in 174 cases (7% of the
cohort). In multivariate analysis, iterative surgical debridements that were performed under
current antibiotic administration were associated with new SSIs (odds ratio 1.6, 95%CI 1.2–
2.2); mostly occurring after the 2nd debridement. However, we failed to define an ideal hypo-
thetic prophylaxis during antibiotic therapy to prevent further SSIs.
Conclusions
Selection of new pathogens resistant to ongoing antibiotic therapy occurs frequently during
iterative debridement in orthopedic infections, especially after the 2nd debridement. The new
pathogens are however unpredictable. The prevention, if feasible, probably relies on
PLOS ONE | https://doi.org/10.1371/journal.pone.0226674 December 18, 2019 1 / 13
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Wuarin L, Abbas M, Harbarth S, Waibel F,
Holy D, Burkhard J, et al. (2019) Changing
perioperative prophylaxis during antibiotic therapy
and iterative debridement for orthopedic
infections? PLoS ONE 14(12): e0226674. https://
doi.org/10.1371/journal.pone.0226674
Editor: Daniel Pe´rez-Prieto, Consorci Parc de Salut
MAR de Barcelona, SPAIN
Received: August 22, 2019
Accepted: December 2, 2019
Published: December 18, 2019
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pone.0226674
Copyright: © 2019 Wuarin et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
surgical performance and wise indications for re-debridement instead of new maximal pro-
phylactic antibiotic coverage in addition to current therapeutic regimens.
Introduction
The ideal regimen for perioperative antibiotic prophylaxis for prevention of surgical site infec-
tions (SSI) is evidence-based for the majority of clean, non-infected orthopedic procedures [1–
4]. However, standard prophylaxis protocols do not recommend specific regimens before re-
debridement of patients under already implemented curative antibiotic therapy for an estab-
lished orthopedic infection (SSI or community-acquired) [1,2]. Scientific literature and epide-
miological evaluations are lacking, but clinicians acknowledge that the microbiological
spectrum may change during the course. The surgical debridement may itself cause new SSI;
or a former SSI may get a new bacterial, postoperative SSI.
Practically, when performing a second look during ongoing antibiotic therapy, surgeons
continue with the current therapeutic antibiotics or, if clinical evolution is unsatisfactory,
empirically broaden the spectrum after obtaining new intraoperative tissue samples. Alterna-
tively, few colleagues administer the standard perioperative prophylaxis, independently of the
pathogens, simply because they lack specific protocols. New intraoperative cultures during re-
operation may remain negative because of the influence of systemic antibiotics [5], but they
might also grow previously unidentified pathogens typically resistant to current antibiotics.
These new pathogens indicate a dilemma. If clinical evolution is satisfactory, physicians
might interpret them as a selection or contamination, and usually continue with the antibiotic
treatment in place. However, besides a pre-planned re-intervention (in order to reduce the
bacterial load surgically), mostly the evolution has been unsatisfactory; hence the indication
for re-debridement. Consequently, these new pathogens are interpreted as new SSIs, with
broadening of the spectrum and prolongation of total antimicrobial therapy [6].
In this study, we aimed to evaluate the missing epidemiology and specifically link the occur-
rence of new SSIs to the numbers of iterative re-debridement that we performed under current
therapeutic antibiotic agents and. We wonder if these patients would profit from extended
prophylaxis during re-debridement; and if the nature of possible secondary SSIs would be
predictable.
Methods
The Geneva University Hospitals is a tertiary center for septic orthopedic surgery and associ-
ated infectiology [7]. For the current study, we used a composite database 2004–2017 (Ethical
Committee no. 13–178, 08–057 [8], 08–06 [9], and 14–198), including all adult patients hospi-
talized for clinically moderate and severe orthopedic infections, including the diabetic foot
[10]). We did not collect tissue samples and did not contact the patients specifically for that
study, but used their old anonymized data to compose our database.
We excluded cases that were amputated in toto [11], cases with antibiotic-free windows
before re-debridement [5], and episodes for which the occurrence of newly identified patho-
gens did not change the antibiotic regimen, because we interpreted them as "contamination",
because the newly detected bacteria had no clinical impact on the further management. In con-
trast, pathogens sensitive to original antibiotic therapy and presumably causative of clinical
worsening, were identified as new pathogens. We defined infection as intraoperative pus and
clinical signs of infection (color, calor, pain). SSI definitions based on the Center of Disease
Iterative surgical site infections
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Control standards [12]. We collected several microbiological samples from deep intraoperative
tissues, and ignored results of superficial specimens or sinus tracts. We regrouped coagulase-
negative staphylococci [13], micrococci, corynebacteria or propionibacteria as “skin commen-
sals”. We assessed the first five pathogens of semi-quantitative cultures and arbitrarily cen-
sored thereafter. The Microbiology Laboratory processed all specimens according to Clinical
and Laboratory Standard’s Institute recommendations [14], before switching to the EUCAST
criteria (European Committee) in 2014 [15].
Of note, besides prior to the very first debridement for orthopedic infection (when the anti-
biotics were first started after intraoperative microbiological samplings), all study patients
were under systemic antibiotic therapy. This therapy was either empirical or targeted to previ-
ously identified pathogens. In this manuscript, the term "prophylaxis" refers to a true perioper-
ative antibiotic prophylaxis, which is only given as a single dose and is not continued after
debridement; independent of current systemic antimicrobial therapy. In contrast, the clinical
changing of antibiotic regimens after/during debridement would be a preemptive, or targeted,
therapeutic change, continuing for several days or weeks.
Statistical analyses
The primary objectives of this study were to determine possible mismatch between current
curative antibiotic therapies and newly identified bacterial superinfection after debridement
and to evaluate the need of a prophylactic antibiotic regimen, in addition to the ongoing cura-
tive antibiotic treatment. We performed group comparisons using the Pearson-χ2 or the Wil-
coxon-ranksum-test. An unmatched multivariate logistic regression analysis determined
associations with the outcome “SSI resistant to antibiotic therapy”. We introduced indepen-
dent variables in the univariate analysis stepwise into the multivariate analysis, except for the
surgical and antibiotic-related parameters, which we forced into the final model. We com-
puted the variables “total number of debridements”, “number of debridements before new
SSI”, and the “time interval between consecutive debridement” as continuous and categorical
variables. The cut-off values of the strata were chosen according to the middle stratum posi-
tioned around the median value of that variable. We further plotted new SSIs according to the
number of prior debridements, and stratified new SSIs according to key pathogen groups. We
used STATA software (9.0, STATA™, USA). P values�0.05 (two-tailed) were significant.
Results
Overall, we included 2480 surgical patients with 2480 first episodes of adult orthopedic infec-
tions. The median age of the patients was 56 years (range, 18–99 y); 784 were females (32%)
and 833 (34%) were immune-suppressed: diabetes mellitus (n = 454) [16], active cancer (113),
severe alcoholism (68), medicamentous immune-depression (62), dialysis (25), cirrhosis
CHILD C (17), solid organ transplantation (10), untreated HIV disease (5), agranulocytosis
(4), splenectomy (1), pregnancy (1), or a combination of immune-suppressed states. We noted
the following infections: implant-related infections (n = 648) [17]; osteoarticular infections
(1153); 1327 soft tissue infections; and 213 diabetic foot infections [10]. We detected 83 differ-
ent microbiological constellations during the initial assessment of infection and 273 newly
acquired bacterial combinations on iterative surgeries. Overall, the five most frequently identi-
fied groups were Staphylococcus aureus (n = 1089; of which 148 methicillin-resistant S. aureus),
streptococci (228), Gram-negatives (498; including 112 Pseudomonas aeruginosa cases [18],
and skin commensals (304) [13]. The index pathogens were Gram-positive, Gram-negative
[19], methicillin-resistant or skin commensals [19] in 1696 (68%), 498 (20%), 143 (6%), 453
Iterative surgical site infections
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(18%), and 304 (12%) cases, respectively. In 558 (22%) and 286 (12%) cases, initial assessments
were polymicrobial and culture-negative [5].
Iterative surgeries under curative antibiotic therapy
All patients were under systemic, curative antibiotic therapy for bacterial infection. We noted
867 different regimens prior to intraoperative samplings; divided upon administration route,
changing during the course, combination therapies and different drug choices. An allocation
of these 867 prior individual antibiotic regimens to the subsequent Overall, 1617 episodes
(65%) were debrided once, compared to 862 cases with multiple debridements (35%); of which
510 a second time and 195 a third time. Formally, the median number of surgical debridement
for infection was 1 (total range, 1–15 interventions; interquartile range, 1–2 interventions).
The median delay between two consecutive interventions was 16 days. In 420 re-debridements
(420/862; 49%), the current antimicrobial agent was continued without additional periopera-
tive prophylaxis. In 90 cases, surgeons or anesthesiologists administered a supplementary stan-
dard prophylaxis with cefuroxime single dose 1.5 g intravenously [1–3,20] in addition to
ongoing therapeutic antibiotics. Clinicians avoided to administer large-spectrum perioperative
prophylaxis and avoided topical antibiotic prophylaxis regimens. Table 1 compares the study
population with single vs. multiple debridements.
In this comparison, patients with bone and joint infections, implant infections, Gram-nega-
tive infections and infections due to skin commensals have been operated significantly more
often than others, whereas sex, age, or immune-suppression did not influence the risk for re-
operation.
New pathogens and new susceptibility profiles according to the number of
iterative surgeries
Among all iterative intraoperative samples during re-debridement, 507 were positive (507/862;
59%), but only 241 (242/507; 48%) returned a species already present in the index debride-
ment. We witnessed thus 265 new pathogens (265/507; 52%) in the same patient. These new
selections were Gram-positive in 192 cases and Gram-negative in 109 episodes and were inter-
preted as (new) SSIs, because of unsatisfactory evolution. As they were resistant to current
antibiotics in 174 cases (174/507; 34%), clinicians broadened the therapeutic antimicrobial
Table 1. Demographic and clinical variables comparing the second look to multiple debridements (>2 lavages).
Second look only Multiple debridements
n = 862 n = 509 p value� n = 353
Female sex 142 (28%) 0.030 123 (35%)
Age (median) 58 years 0.119 61 years
Immunosuppression+ 166 (33%) 0.754 126 (36%)
Implant infections 192 (38%) 0.013 163 (46%)
Bone and joint infections 305 (60%) 0.038 236 (67%)
Diabetic foot infections 37 (7%) 0.100 16 (5%)
Polymicrobial infections 108 (21%) 0.004 105 (30%)
Initial Gram-positive infections 367 (72%) 0.009 225 (64%)
Initial Gram-negative infections 97 (19%) 0.001 105 (30%)
� Significant p values�0.05 are displayed in bold and italic.
+ Immunosuppression = diabetes mellitus, corticosteroid medication, organ transplantation, cirrhosis CHILD C, dialysis, cancer, untreated HIV disease, alcohol
dependency, pregnancy, agranulocytosis, splenectomy
https://doi.org/10.1371/journal.pone.0226674.t001
Iterative surgical site infections
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spectrum and prolonged therapy. In contrast, 333 new pathogens were susceptible to the prior
antibiotics. To cite an example, the overall proportion of methicillin-susceptible S. aureus
among the causative pathogens had fallen from 38% to 11%, that of streptococci from 16% to
9% [21], while the proportion of methicillin-resistant S. aureus [8], enterococci [22], and non-
fermenting rods [19] rose up significantly (Fig 1).
Stratified upon the groups of bone and joint infections, soft tissue and diabetic foot infec-
tions, the overall proportion of resistant new SSI were 13% (145/1153), 9% (120/1327), and
14% (30/213), respectively.
Table 2 shows clinical variables related to new antibiotic-resistant SSIs. The number of
prior surgical debridements (all under current systemic antibiotic therapy) were significantly
associated with the occurrence of new pathogens; independent of the initial pathogens. These
new resistant SSIs were unpredictable regarding the microbiology and distributed among the
entire Gram-positive and Gram-negative spectrum (Table 2; Fig 2A) with, however, a ten-
dency towards more Gram-negatives with increasing numbers of surgical interventions, age,
and a shorter delay between consecutive debridement (Table 3).
Fig 1. Changes of intraoperative pathogens (selected examples) from the first debridement to the third debridement for the same orthopedic infection.
MSSA = Methicillin-susceptible Staphylococcus aureus. MRSA = Methicillin-resistant Staphylococcus aureus. P. aeruginosa = Pseudomonas aeruginosa.
https://doi.org/10.1371/journal.pone.0226674.g001
Iterative surgical site infections
PLOS ONE | https://doi.org/10.1371/journal.pone.0226674 December 18, 2019 5 / 13
Patients’ sex, immune-suppression or localization of the orthopedic infections did not
influence epidemiology. Table 4 summaries these new pathogens.
Many are naturally resistant to usual, narrow-spectrum β-lactam antibiotics (e.g. penicillins
and 1st or 2nd generation cephalosporins). Of note, during the study period there was no spe-
cific outbreak in the septic orthopedic ward with the exception of five cases of vancomycin-
resistant enterococci (VRE). The endemicity of methicillin-resistant S. aureus declined
throughout the study period [8], and that of ESBL is rising [23]. Regarding the timing, new
SSIs mostly peaked after the 2nd and 3rd debridement. Indeed, the microbiology during the
first re-debridement still reveals two-thirds of known pathogens and one-third of new constel-
lations. But already the second and third re-debridement switches to a third known pathogens
and two-thirds of new ones (Fig 3).
Multivariate adjustment
In view of the considerable case-mix, we adjusted with logistic regression analysis. We con-
firmed that with the occurrence of new antibiotic-resistant SSIs under current systemic antibi-
otic therapy and iterative surgeries (odds ratio 1.6, 95% confidence interval 1.2–2.2), (Table 5).
Of note, since all patients undergoing iterative debridement were already under systemic anti-
biotic administration, we could not determine the impact of iterative surgeries alone (without
concomitant antibiotic therapies) on the occurrence of these new SSI’s.
Already the second debridement substantial under antibiotic treatment increased the odds
ratio of new SSIs to twelve. In contrast, sex, age, and immune-suppression were unrelated. The
Table 2. Characteristics of resistant pathogens in repetitive intraoperative samples performed under current antibiotic therapy (Some episodes have mixed new
Gram-positive and Gram-negative infections, which we display separately in both lateral columns).
New Gram-
positives
Absence of new germs,
n = 91
Absence of new germs,
n = 174
New Gram-
negatives
n = 283 n = 192 p value� (Gram-positive) (Gram-negative) p value� n = 109
Female sex 57 (30%) 0.606 701 (32%) 701 (32%) 0.763 36 (33%)
Age (median) 63 years 0.250 56 years 56 years 0.413 59 years
Immunosuppression+ 73 (38%) 0.146 732 (33%) 732 (33%) 0.042 50 (46%)
Median numbers of prior
debridements
2 0.035 1 1 0.028 2
Prior (amino)penicillin therapy 106 (55%) 0.463 46 (51%) 42 (24%) 0.525 30 (28%)
Prior 1st-3rd generation cephalosporins 21 (11%) 0.789 9 (10%) 20 (11%) 0.537 10 (9%)
Prior glycopeptide & daptomycin
therapy
5 (3%) 0.219 5 (5%) 4 (3%) 0.155 6 (6%)
Prior carbapenem & tazobactam
therapy
14 (7%) 0.455 9 (10%) 13 (7%) 0.610 10 (9%)
Implant-associated infections 65 (34%) 0.740 29 (32%) 65 (37%) 0.062 29 (27%)
Osteoarticular infection 106 (55%) 0.463 46 (51%) 100 (58%) 0.109 52 (48%)
Initial polymicrobial infections 86 (45%) 0.760 39 (43%) 73 (42%) 0.343 52 (48%)
Initial Gram-positive infections 109 (57%) 0.001 1535 (69%) 1535 (69%) 0.128 68 (62%)
Initial Gram-negative infections 66 (35%) 0.001 413 (19%) 413 (19%) 0.001 37 (34%)
Initial skin commensal infections˚ 32 (17%) 0.034 256 (12%) 256 (12%) 0.032 20 (18%)
� Significant p values�0.05 are displayed in bold and italic.
+ Immunosuppression = diabetes mellitus, corticosteroid medication, organ transplantation, cirrhosis CHILD C, dialysis, cancer, untreated HIV disease, alcohol
dependency, pregnancy, agranulocytosis, splenectomy
˚ Skin commensals = coagulase-negative staphylococci, micrococci, corynebacteria or propionibacteria
https://doi.org/10.1371/journal.pone.0226674.t002
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goodness-of-fit test was insignificant (p = 0.41) and the Receiver-Operating Curve value 0.86;
showing a good accuracy of our final model.
Fig 2. Total number of new pathogens (vertical axis) stratified upon the Gram coloration and the number of debridement (horizontal axis).
https://doi.org/10.1371/journal.pone.0226674.g002
Table 3. Comparison between new Gram-positive and new Gram-negative surgical site infection under ongoing antibiotic therapy (Some episodes have mixed new
Gram-positive and Gram-negative infections, which we display in both columns).
Gram-positive infections Gram-negative infections
n = 301 n = 191 p value� n = 109
Female sex 57 (30%) 0.566 36 (33%)
Age (median) 59 years 0.023 61 years
Immunosuppression+ 73 (38%) 0.195 50 (46%)
Implant infections 65 (34%) 0.182 29 (27%)
Bone and joint infections 106 (55%) 0.592 52 (48%)
Soft tissue infections 85 (45%) 0.592 57 (52%)
Median total number of debridements 2 0.001 3
Median number of debridements before new infection 2 0.001 2
Median delay between two debridements 29 days 0.001 22 days
� Significant p values�0.05 are displayed in bold and italic.
+ Immunosuppression = diabetes mellitus, corticosteroid medication, organ transplantation, cirrhosis CHILD C, dialysis, cancer, untreated HIV disease, alcohol
dependency, pregnancy, agranulocytosis, splenectomy
https://doi.org/10.1371/journal.pone.0226674.t003
Iterative surgical site infections
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Discussion
This study provides insights in the complex epidemiology of iterative SSIs during multiple
debridements and current antibiotic therapy for orthopedic infections. It is an original work,
with a large number of patients included in an analysis from a retrospective database. Among
2480 adult patients, we re-debrided a third, and a quarter revealed new pathogens. Totally,
Table 4. New pathogens and new orthopaedic surgical site infections during current antibiotic treatment (n = 273).
Gram-positives Number Gram-negatives Number Anaerobes and fungi Number
Coagulase-negative staphylococci 106 Enterobacter 31 Bacteroides 4
Enterococci 34 Pseudomonas 32 Peptostreptococci 4
Staphylococcus aureus (susceptible) 24 Escherichia coli 20 Peptoniphilus 1
Staphylococcus aureus (resistant) 22 Klebsiella 15
Streptococci 17 Proteus 14
Corynebacterium 9 Morganella 8
Propionibacteria 5 Citrobacter 5
Bacillus 3 Serratia 4
Micrococci 3 Acinetobacter 3
Clostridium 3 Aeromonas 2
Actinomyces 2 Veillonella 1
Salmonella 1
Prevotella 1
Providencia 1 Candida 5
https://doi.org/10.1371/journal.pone.0226674.t004
Fig 3. Proportions of known versus newly identified pathogens (vertical axis) stratified upon the number of debridement (horizontal axis).
https://doi.org/10.1371/journal.pone.0226674.g003
Iterative surgical site infections
PLOS ONE | https://doi.org/10.1371/journal.pone.0226674 December 18, 2019 8 / 13
around ten percent of all episodes had new bacterial SSIs; with resistance to ongoing antibiotic
agent in seven percent. From a clinical perspective, among 862 patients that required a re-
debridement, 507 (59%) revealed a positive culture. In 265 (52%) the isolated microorganisms
were different from the prior debridement. This means that from all episodes that required re-
debridement, 30.7% (265) had a different pathogen. This is a major problem, particularly con-
sidered that the new microorganisms were often more resistant.
Since we only included relevant cases with immediate adaptation of the antibiotic therapy,
we think that our interpretation of new SSIs is genuine and we are not facing mere selection
and contamination. We think that it is nearly impossible to study our hypotheses in any other
prospective and more controlled way. Moreover, the majority of the new microorganisms are
undisputed pathogens for orthopedic SSIs [20] in Switzerland.
Available literature is very sparse. We identified only a single Spanish article with a similar
study question, but in a very different setting. Ballus et al. published the epidemiology of surgi-
cal site peritonitis in an intensive care unit with broad-spectrum antibiotic use [6]. They pro-
spectively observed 162 adult patients. Microorganisms isolated from tertiary peritonitis SSI’s
(160 cases; after combined surgical and medical treatment of previous episodes) revealed
higher antibiotic-resistance (65%) than primary peritonitis. Every clinician would confirm this
experience similar to our findings. Unfortunately, the authors lacked specific suggestions in
terms of prevention of tertiary peritonitis, let alone concerning its optimal perioperative pro-
phylaxis [6].
The legitime question is how much of these new SSI pathogens can be prevented by a modi-
fied or additional single-dose prophylaxis upon iterative debridement. The reason for a new
SSI could be the consequence of miss-identification during the first surgery, new contamina-
tion during previous surgery for infection or superinfection of the wound on the ward despite
current therapeutic antibiotic administration. Considering only the first two options as pre-
ventable, the third is not modifiable by any additional antibiotic administration. Clinically, the
novel incidence of 7–11% SSIs warrants adaptation of perioperative prophylaxis for the first
Table 5. Univariate and multivariate associations with resistant new SSI’s (Logistic regression analysis; results expressed as odds ratios with 95% confidence
intervals).
Univariate analysis Multivariate analysis
Female sex 1.0, 0.7–1.3 0.9, 0.6–1.3
Age 1.0, 1.0–1.1� 1.0, 1.0–1.0
Immunosuppression+ 1.2, 0.9–1.6 1.1, 0.8–1.6
Implant infections 1.6, 1.2–2.0� 0.9, 0.6–1.4
Bone and joint infections 1.4, 1.1–1.9� n.d.
Total number of debridements 2.2, 2.0–2.4� 1.7, 1.3–2.1�
- 2 debridements compared to 1 12.8, 8.3–19.8� 13.7, 8.8–21.2�
- 3 debridements compared to 1 31.8, 19.8–52.1� 33.7, 20.7–54.6�
- 4 debridements compared to 1 48.7, 30.0–79.4� 52.8, 31.9–87.4�
No. of debridements until new infection 1.2, 1.1–1.3� 0.9, 0.8–1.1
-� 1 debridements compared to 1 2.9, 2.0–4.1� n.d.
Time delay between two debridements 1.0. 1.0–1.1� 1.0, 1.0–1.1�
- 6–16 days compared to� 5 days 4.0, 2.3–7.5� 3.3, 1.7–6.3�
- 17–46 days compared to� 5 days 8.1, 4.4–14.8� 5.6, 2.7–10.7�
� Statistically significant results are displayed in bold and italic. n. d. = not done
+ Immunosuppression = diabetes mellitus, corticosteroid medication, organ transplantation, cirrhosis CHILD C, dialysis, cancer, untreated HIV disease, alcohol
dependency, pregnancy, agranulocytosis, splenectomy
https://doi.org/10.1371/journal.pone.0226674.t005
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and second conceptual situations. Standard second-generation cephalosporins or vancomycin
[1–3] lack the necessary coverage in view of the random nature of the new pathogens. Unfortu-
nately, we equally failed identifying a specific microbiological pattern to tailor a specific pro-
phylaxis regimen. New postoperative superinfections appear Gram-positive, Gram-negative or
both and include dozens of pathogen combinations; and this independently of initial patho-
gens, initial antimicrobial therapies, orthopedic infections or patient characteristics. An opti-
mal total prophylactic coverage would hence theoretically consist of a combination of
glycopeptides with aminoglycosides, or glycopeptides with carbapenems, piperacillin-tazobac-
tam and similar spectra. Also, in some selected cases, a partial supplementary prophylaxis may
be added on. For example, in patients treated with narrow-spectrum penicillin for streptococ-
cal infections and multiple debridements, perhaps the combination with vancomycin might be
sometimes indicated, but this is no maximal coverage by far and still needs to be proven as
beneficiary.
However, unless there are future published clinical trials, we advocate against the introduc-
tion of this near-maximal prophylaxis because of the following reasons: First, perioperative
prophylaxis is only one cornerstone of SSI prevention. It must be embedded in a whole bundle
of measures [1–3]. Alone, it only reduces absolute SSI risks by some few percent [1]. Second,
enhanced antibiotic prophylaxis lacks its final proofs, but might be associated with unneces-
sary adverse events (even when it is in single doses [24] or administered during three days
such as in open fractures [4]). Several author groups proposed different enhancement strate-
gies for non-infected orthopedic surgery: combining with local prophylaxis (e.g. local vanco-
mycin in spine surgery [25]), double prophylaxis against Gram-negative [26] and Gram-
positive [27] pathogens, or universal glycopeptide prophylaxis [28]. The majority of these
enhancements failed to reduce SSI risk. Exceptions remain rare, very specific and often not
reproducible by other research groups. At the same time, numerous reports documented tran-
sient kidney injuries by aminoglycosides [27] or combined vancomycin prophylaxis [28] in
orthopedic surgery. Walker et al. reported that following a change in prophylaxis (from floxa-
cillin & gentamycin to amoxicillin/clavulanic acid), they witnessed a 63% decrease in postoper-
ative renal insufficiencies [29]. Moreover, enlarged prophylaxes, if implemented during a long
period, could alter endemicity in septic orthopedics wards towards more resistant and Gram-
negative pathogens [23].
Besides the fact that our study is retrospective, it has five major limitations. First, we ignore
the acquisition route and the exact timing of the first presence and onset of the new SSI patho-
gens. We ignore if they were already colonizing the patient from the start, if they were present
in the initial wound and subsequently selected by inactive antibiotics, or if they are true new
acquisitions. Second, consequences of microbiological findings are arbitrary by nature. Infec-
tious diseases physicians are often absent during surgery [7]. They have to decide the antibiotic
changes, but are depending on the microbiological laboratory and especially upon the sur-
geons regarding clinical interpretation of the clinic and microbiological results (e.g. hema-
toma/seroma versus pus). Likewise, even if some new pathogens are clearly pathogenic, others
might be not. Thus, in polymicrobial SSIs, it is quasi impossible to judge which of the patho-
gens is causative and which one is contamination. Moreover, new bacteria can also be a true
new SSI that was simply not severe enough to worsen the clinical evolution. In that sense,
when there is good clinical evolution, it is impossible to distinguish between colonization and
clinical new infection. Third, although we analyzed many confounders, there are still some
important variables unnoted, such as hand hygiene compliance [1], post-operative non-infec-
tious wound complications [30] or use of negative-pressure vacuum therapy. Likewise, all
patients undergoing iterative surgeries for infection, were already under systemic antibiotic
therapy during re-debridement. Hence, we cannot pronounce on the possibility of
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microbiological changes during iterative debridement in absence of antibiotic treatment.
Fourth, in our study population, we had 83 different antibiotic regimens and an occurrence of
273 new pathogens. We moreover add a variety of 867 new antibiotic regimen changes
throughout the therapeutic course in our study population. Such mixed constellations become
too much detailed to be analyzed individually or to be individually displayed. We must recur
to group analysis. Fifth, we limited the assessment of pathogens to the five most dominant
ones in line with usual clinical practice. It is clear that a full microbiological work-up and a
prolongation of the incubation time, beyond the standard five days, could alter overall epide-
miological results.
Conclusions
According to our cohort of 2480 adult patients with orthopedic infections, new SSIs occur at
ten percent’s risk during iterative debridement and concomitant antibiotic therapy. They
already predominate after the 2nd debridement and are often resistant to administered antibi-
otics. Their microbial etiology seems unpredictable. We argue nevertheless against a total pro-
phylactic coverage without prior prospective trials due to potential adverse effects and call for
strict adherence to general infection control policies, evidence-based indications for surgical
re-debridement and skilled surgical techniques [1–4]. The role of partial and selected enhance-
ments of prophylaxis needs to be elucidated separately.
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